Markets
markets

Pfizer to buy obesity drug developer Metsera for up to $7.3 billion

Pfizer rose in premarket trading after it announced that it would acquire anti-obesity drug developer Metsera, which puts the pharmaceutical giant back in the weight-loss medication game after its own pill didn’t advance to the final stages of trials.

The transaction is a valued at $47.50 per share (roughly $4.9 billion by enterprise value), which could rise to $70 per share (or $7.3 billion) if certain clinical and regulatory milestones are met. Metsera closed at $33.32 on Friday and shot up nearly 60% in premarket trading.

The deal, which was paid for with a combination of cash and debt, is expected to close by the end of the year.

Metsera is developing a weight-loss shot (called MET-233i) that has shown promise but is still in early trials, meaning it will likely be years before it reaches patients. Notably, the shot is able to be taken monthly rather than weekly like the GLP-1 shots currently on the market made by Eli Lilly and Novo Nordisk.

More Markets

See all Markets
markets

Memory chip makers bounce back after report of customers turning to China for supplies

High-flying memory chip stocks like Sandisk and Micron bounced back early Thursday after dropping in pre-market trading following a Nikkei report that some PC makers are considering turning to Chinese companies — such as ChangXin Memory Technologies — for supplies amid a historic chip price spike sent them down in the premarket session.

markets

Nio projects its first quarterly profit, sending shares surging

Chinese EV maker Nio on Thursday said it expects to achieve its first-ever quarterly profit in its fourth quarter. Its US-traded ADRs rose more than 6% in premarket trading.

Based on a preliminary assessment, Nio projects Q4 adjusted profit from operations of between $100 million and $172 million. Wall Street analysts polled by FactSet estimated a Q4 adjusted operating loss of $19 million.

Nio attributed the preliminary results to sustained sales volume growth, vehicle margin optimization, and cost reductions. Nio delivered 124,807 vehicles in its fourth quarter, which ended in December, up 72% year over year.

(Hims & Hers compounded semaglutdie)

Hims to offer copies of Wegovy pill at $49 a month for starting dose, Novo threatens legal action

Novo said in a statement "will take legal and regulatory action to protect patients, our intellectual property and the integrity of the US gold-standard drug approval framework."

markets

Nvidia rebounds after Foxconn posts massive sales growth in January, highlights increasing demand for AI racks

Nvidia is rebounding from its worst five-session decline since April this morning after Hon Hai Technology Group posted massive sales growth for January, up 35.5% year on year.

Hon Hai, more commonly known as Foxconn, indicated that its cloud and networking products division (which includes servers for data centers) was its top source of sales growth.

“Shipments of AI racks continue to increase,” the electronics manufacturer said. “The seasonal performance for the current quarter is expected to be better than the range of the past five years.”

Near the start of 2026, Micron soared after Hon Hai announced better-than-expected Q4 sales.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.